CRIS CURIS INC
Price Chart
Executive Summary
Curis Inc. shareholders approved a charter amendment at the May 19, 2026 annual meeting to nearly double authorized common shares from 283.8M to 567.5M, providing substantial future dilution capacity. Simultaneously, the company eliminated the Certificate of Designations for its Series A and B Preferred Stock, returning those shares to undesignated authorized preferred status. For a micro-cap biotech with a ~$19M market cap, the massive authorized share increase signals potential future capital raises, but no immediate offering is announced.
Actionable Insight
The authorized share increase is a near-term dilutive signal for a micro-cap biotech — watch for an overnight S-3 shelf filing or registered direct offering in coming weeks. The Series B conversion in March already added ~20M shares of overhang; this filing clears deck for further financing. Monitor for any ATM program or public offering announcement.
Key Facts
- Authorized common shares increased from 283,757,150 to 567,514,300 (near-doubling).
- Total authorized capital stock increased from 288,757,150 to 572,514,300 shares.
- Series A and Series B Preferred Stock certificate of designations eliminated; preferred shares returned to undesignated authorized status.
- All proposals at the Annual Meeting passed, including director elections, executive compensation (non-binding), auditor ratification, and the share increase.
- Series B Preferred Stock (20,195 shares) had been auto-converted to common and pre-funded warrants in March 2026.
- Current market cap is ~$19M; the company is a pre-revenue clinical-stage biotech.
Financial Impact
Authorized common shares nearly doubled to 567.5M shares; no immediate pricing or offering attached. The company now has capacity to issue over 280M additional shares.
Risk Factors
- Substantial future dilution from the ~284M newly authorized but unissued common shares.
- Potential near-term equity financing given micro-cap capitalization and clinical-stage pipeline needs.
- No revenue disclosed; cash runway not stated — financing likely needed for operations.
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001108205-26-000065 |
| Document: cris-8xk_exh32xcertificate.htm | 0001108205-26-000065 |
| Document: cris-8xk_exh31xcharteramen.htm | 0001108205-26-000065 |
| Document: 0001108205-26-000065-index-headers.html | 0001108205-26-000065 |
| Document: 0001108205-26-000065-index.html | 0001108205-26-000065 |
| Document: 0001108205-26-000065.txt | 0001108205-26-000065 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 22, 2026
21d ago
|
8-K
| $0.4900 $0.5000 | ▼ −2.04% | ▼ −0.83% | $0.4200 (+14.29%) |
|
May 12, 2026
4w ago
|
8-K
| $0.5000 $0.4800 | ▲ +4.00% | ▲ +2.84% | $0.4200 (+16.00%) |
|
May 1, 2026
6w ago
|
8-K
| $0.5800 $0.5500 | ▲ +5.17% | ▲ +8.11% | $0.4200 (+27.59%) |
|
Mar 23, 2026
11w ago
|
EFFECT
| $0.7400 $0.5100 | ▼ −31.08% | ▼ −27.52% | $0.4200 (−43.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access